AVITA Medical, Inc. RCEL
AVITA Medical is a leading therapeutic acute wound care company delivering transformative solutions designed to optimize wound healing, accelerate patient recovery, and improve clinical and economic outcomes across the continuum of acute wound management. Our technologies address critical healing needs arising from burns, traumatic injuries and surgical repairs, through a portfolio of proprietary and complementary products that support wound bed preparation, definitive closure, and recovery.
Our current commercial portfolio includes RECELL® ("RECELL"), and two complementary wound care products, PermeaDerm® and Cohealyx, which together support a comprehensive standard of care for acute wounds.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.9M | $63.9M | $50.1M | $34.4M | $29.2M | $14.3M | $5.5M | $929.0K | — |
| Cost of revenue | $12.8M | $9.1M | $7.8M | $6.0M | $5.9M | $3.0M | $1.3M | $546.0K | — |
| Gross profit | $58.8M | $55.2M | $42.4M | $28.4M | $23.3M | $11.3M | $4.2M | $383.0K | — |
| R&D | $20.8M | $20.4M | $20.8M | $13.9M | $14.8M | $9.2M | $8.0M | $6.3M | — |
| SG&A | $27.4M | $33.2M | $28.3M | $23.3M | $22.4M | $33.0M | $15.1M | $9.4M | — |
| Total operating expenses | $101.3M | $111.8M | $86.4M | $59.1M | $51.9M | $57.9M | $35.7M | $22.0M | — |
| Operating income | -$42.5M | -$56.6M | -$42.7M | -$27.5M | -$26.5M | -$42.7M | -$25.5M | -$13.8M | — |
| Interest expense | $5.0M | $5.4M | $1.1M | $16.0K | $22.0K | $33.0K | $27.0K | $21.0K | — |
| Pre-tax income | -$48.6M | -$61.8M | -$35.3M | -$26.6M | -$26.5M | -$42.0M | -$25.2M | -$13.8M | — |
| Income tax | $11.0K | $54.0K | $66.0K | $36.0K | $38.0K | $4.0K | $121.0K | $1.1M | — |
| Net income | -$48.6M | -$61.8M | -$35.4M | -$26.7M | -$26.6M | -$42.0M | -$25.1M | -$12.7M | — |
| EPS, basic | -1.74 | -2.39 | -1.40 | 1.07 | 1.17 | 2.07 | 1.56 | 1.37 | — |
| EPS, diluted | -1.74 | -2.39 | -1.40 | 1.07 | 1.17 | 2.07 | 1.56 | 1.37 | — |
| Shares, diluted (wtd. avg.) | $27.9M | $25.9M | $25.3M | $25.0M | $22.7M | $20.3M | $16.1M | $9.3M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $10.2M | $14.1M | $22.1M | $18.2M | $55.7M | $73.8M | $20.4M | $11.0M | $2.9M |
| Short-term investments | $7.9M | $21.8M | $66.9M | $61.2M | $29.6M | — | — | — | — |
| Receivables | $9.1M | $11.8M | $7.7M | $3.5M | $3.5M | $2.1M | $1.4M | — | — |
| Inventory | $6.9M | $7.3M | $5.6M | $2.1M | $1.6M | $1.1M | $742.0K | — | — |
| Total current assets | $35.5M | $57.0M | $104.0M | $87.5M | $121.3M | $78.4M | $24.1M | — | — |
| Property, plant and equipment | $8.6M | $10.0M | $1.9M | $1.2M | $1.5M | $1.4M | $1.3M | — | — |
| Other intangibles | $5.6M | $5.6M | $487.0K | $465.0K | $472.0K | $364.0K | $225.0K | — | — |
| Total assets | $56.4M | $79.7M | $111.6M | $98.3M | $125.5M | $82.5M | $25.8M | — | — |
| Accounts payable | $9.0M | $6.3M | $3.8M | $3.0M | $3.1M | $4.3M | $1.9M | — | — |
| Short-term debt | $43.0M | $0 | — | — | — | — | — | — | — |
| Total current liabilities | $62.7M | $20.2M | $13.2M | $10.7M | $7.4M | $7.7M | $4.5M | — | — |
| Long-term debt | $0 | $42.2M | $39.8M | — | — | — | — | — | — |
| Total liabilities | $73.0M | $75.0M | $61.9M | $13.0M | $9.8M | $10.1M | $5.0M | — | — |
| Retained earnings | -$408.4M | -$359.8M | -$298.0M | -$262.6M | -$221.5M | -$194.9M | -$152.8M | — | — |
| Total equity | -$16.6M | $4.5M | $49.1M | $84.7M | $104.6M | $72.4M | $20.8M | $14.0M | $3.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.2M | -$48.9M | -$38.0M | -$19.1M | -$25.9M | -$22.7M | -$19.2M | -$13.0M | — |
| Depreciation and amortisation | $2.3M | $1.1M | $632.0K | $568.0K | $715.0K | $465.0K | $269.0K | $110.0K | — |
| Stock-based compensation | $9.5M | $13.5M | $8.4M | $7.0M | $5.7M | $16.5M | $1.9M | $1.4M | — |
| Capital expenditure | $1.0M | $9.2M | $1.4M | $452.0K | $894.0K | $590.0K | $1.0M | $365.0K | — |
| Investing cash flow | $12.5M | $37.4M | $1.6M | -$19.3M | -$1.2M | -$847.0K | -$1.2M | -$365.0K | — |
| Financing cash flow | $14.9M | $3.5M | $40.4M | $900.0K | $64.0M | $77.1M | $29.7M | $21.3M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-049031.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |